Drugs / HB-adMSCs (allogeneic)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05126563 Comparator | Feb 2022 → Apr 2024 | post-COVID-19 disorder | Hope Biosciences Research Foundation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-adMSCs (allogeneic) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05126563 ↗ |
| Modality | Cell therapy | “Hope Biosciences adipose-derived mesenchymal stem cells - allogeneic” NCT05126563 ↗ |
| Route | Intravenous | “Route: Intravenous” NCT05126563 ↗ |